A detailed history of Mariner, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Mariner, LLC holds 21,854 shares of IONS stock, worth $882,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,854
Previous 20,784 5.15%
Holding current value
$882,027
Previous $900,000 15.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$36.45 - $47.7 $39,001 - $51,039
1,070 Added 5.15%
21,854 $1.04 Million
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $4,707 - $5,997
112 Added 0.54%
20,784 $900,000
Q4 2023

Feb 14, 2024

BUY
$43.39 - $51.63 $120,797 - $143,737
2,784 Added 15.56%
20,672 $1.05 Million
Q3 2023

Nov 13, 2023

BUY
$38.5 - $47.13 $19,789 - $24,224
514 Added 2.96%
17,888 $811,000
Q2 2023

Aug 11, 2023

BUY
$34.73 - $43.33 $376,924 - $470,260
10,853 Added 166.43%
17,374 $712,000
Q1 2023

May 12, 2023

SELL
$33.58 - $41.2 $370,085 - $454,065
-11,021 Reduced 62.83%
6,521 $233,000
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $386,085 - $483,854
10,401 Added 145.65%
17,542 $663,000
Q3 2022

Nov 10, 2022

BUY
$36.54 - $48.66 $260,932 - $347,481
7,141 New
7,141 $316,000
Q3 2019

Nov 13, 2019

SELL
$59.06 - $72.15 $194,720 - $237,878
-3,297 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$62.09 - $86.14 $3,973 - $5,512
64 Added 1.98%
3,297 $212,000
Q1 2019

May 15, 2019

SELL
$52.92 - $81.17 $131,082 - $201,058
-2,477 Reduced 43.38%
3,233 $262,000
Q4 2018

Feb 13, 2019

BUY
$43.37 - $59.54 $247,642 - $339,973
5,710 New
5,710 $309,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.73B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.